General AML

How close are we to implementing germline precision medicine in acute myeloid leukemia?

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jane Churpek, The University of Wisconsin, Madison, US. We discussed, how close we are to implementing germline precision medicine in acute myeloid leukemia.

In recent years, researchers started to look at how many patients who develop myeloid diseases have a germline predisposition and what is the impacts of these mutations on patient prognosis.